课题基金 / 基金详情

Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection

Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection
主动脉瘤和急性主动脉夹层的新型生物标志物
批准号:
7935405
负责人:
Harry C., III Dietz
金额:
$49.82万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-08-31

项目摘要

项目成果

Harry C., III Dietz的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请涉及广泛的挑战领域(06)“使能技术”和特定的变更主题06- HL-101“开发用于评估易破裂或夹层的主动脉瘤的技术”。主动脉夹层描述了身体主要血管主动脉壁的撕裂。潜在的病理学多种多样,诱发因素包括主动脉瘤和结缔组织疾病。这是一种危及生命的事件,特别是如果夹层位于胸主动脉的升段,因为它可能通过损害主动脉瓣和通过冠状动脉的血流而导致全身心肌缺血。主动脉破裂更为罕见,但几乎总是与100%的死亡率相关。在目前的提案中,我们解决了临床相关和迫切需要阐明的机制,(i)将使我们能够识别患者中的风险为夹层已知的主动脉瘤患者(ii)促进诊断主动脉夹层的急性胸痛患者和(iii)帮助我们个性化治疗。主动脉扩张是由多种机制引起的,包括遗传性结缔组织疾病,如马凡氏综合征(MFS)。我们将使用MFS作为主动脉疾病的模型,因为我们已经表明,全面了解这种疾病提供了更好的了解血管壁生物学,并确定相关的途径,主动脉瘤和夹层一般。在2006年,我们发现过度的TGF β信号在MFS小鼠模型的发病机制中起着重要作用。已经通过从头发现鉴定了几种候选标记物,其中之一是TGF β。我们可以证明,用氯沙坦(一种AT 1拮抗剂)阻断小鼠的TGF β通路,可以使主动脉壁结构正常化。我们最近证实,小鼠模型中的循环TGF β水平显著高于野生型小鼠。此外,通过施用氯沙坦降低循环TGF β的水平。最近发表的结果表明,在儿童人群中,将氯沙坦添加到标准治疗中可显著降低主动脉生长速率。约翰霍普金斯是GenTAC注册中心的一部分,该中心招募了来自广泛遗传性疾病的主动脉瘤患者。最近,我们获得许可,对登记研究中招募的前207名MFS患者的TGF β水平进行分析,与对照患者相比,可能显示出非常显着的增加。在目前的提案中,我们将(目标1)继续我们在MFS小鼠模型中的发现工作,并使用免疫测定和MRM(一种基于质谱的突破性技术,允许抗体独立定量)在小鼠和GenTAC群体中验证我们的候选标记物。在第二步(目标2)中,我们在小鼠中建立了急性主动脉夹层模型。这将使我们能够将从头发现扩展到急性环境,并弥合急性夹层患者生物标志物发现的差距。我们将使用免疫测定和MRM验证我们的候选标记物,从而进一步了解主动脉夹层的预后。由于TGF β家族已被证明在MFS的发展中起关键作用,我们的目标是开发一种能够在有限量的样品中同时测量TGF β-1,-2和-3的多重测定法(Aim 3)。我们最近获得了测量唾液中TGF β的能力。这可能是一个有吸引力的选择,“筛选”患者的动脉瘤活动,并为个体患者的治疗提供指导。由于主动脉疾病的许多方面,包括诊断程序和治疗措施,结缔组织病患者与非综合征背景的患者相似,因此当前项目的见解将有助于对主动脉疾病患者的护理。每年约翰霍普金斯学院直接在马里兰州产生约100亿美元的经济活动,比2002年产生的70亿美元增加了43%,相当于今天该州经济中的每24美元。2008年,约翰霍普金斯机构提供了45,000个工作岗位,自2002年以来每年创造700个新工作岗位。约翰霍普金斯学院直接和间接地为马里兰州提供了10万多个工作岗位,是该州每29个工作岗位中的一个。仅在巴尔的摩市,约翰霍普金斯大学就直接和间接提供了6万个工作岗位,占该市所有就业岗位的16.7%。 公共卫生相关性:在工业化国家,主动脉瘤的急性夹层和破裂占所有死亡的1-2%。临床上迫切需要找到一种机制,能够(i)使我们能够在已知的主动脉瘤患者中识别有夹层风险的患者,(ii)促进急性胸痛患者的主动脉夹层诊断,(iii)帮助我们进行个体化治疗。目前的提案将在先进的主动脉瘤和夹层动物模型中使用蛋白质组学技术,以深入了解这些机制,并在大量主动脉疾病患者中验证研究结果。
英文摘要
DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (06) "Enabling Technologies" and specific Change Topic, 06- HL-101 "Developing technologies for assessment of aortic aneurysms prone to rupture or dissection". Aortic dissection describes a tear in the wall of the main vessel in the body, the aorta. The underlying pathology is diverse and predisposing factors include aortic aneurysms and diseases of the connective tissue. This is a life-threatening event, especially if the dissection is located in the ascending part of the thoracic aorta since it may lead to global myocardial ischemia by compromising the aortic valve and blood flow through the coronary arteries. Rupture of the aorta is more rare but almost always associated with a 100% mortality. In the current proposal we address a clinically relevant and pressing need to elucidate the mechanisms that (i) would enable us to identify the patient at risk for a dissection among patients with known aortic aneurysms (ii) facilitate diagnosis of aortic dissection in the patient with acute chest pain and (iii) helps us to individualize therapy. Dilation of the aorta is caused by a multitude of mechanisms including inherited connective tissue disorders such as Marfan syndrome (MFS). We will use MFS as a model for aortic diseases in the current proposal since we have already shown that a comprehensive understanding of this disorder provides greater understanding of vascular wall biology and identifies pathways relevant to aortic aneurysms and dissection in general. In 2006, we showed that excessive TGFbeta signaling plays a major role in the pathogenesis of MFS in a mouse model for MFS. Several candidate markers have been identified by de novo discovery, with one of them being TGFbeta. We could prove that blocking the TGFbeta pathway in the mouse with losartan, an AT1-anatgonist, normalizes aortic wall architecture. We recently demonstrated that circulating TGFbeta levels in the mouse model are significantly higher than in wild-type mice. Furthermore, levels of circulating TGFbeta are decreased by administration of losartan. Recently published results of adding losartan to standard therapy in a pediatric population demonstrated a significant decrease in aortic growth rate. Johns Hopkins is part of the GenTAC registry, which enrolls patients with aortic aneurysms from a broad spectrum of heritable disorders. Recently, we obtained permission to analyze the first 207 patients with MFS enrolled in the registry for levels of TGFbeta and could demonstrate a highly significant increase compared to control patients. In the current proposal we will (Aim 1) continue our discovery work in the mouse model for MFS and validate our candidate marker in the mice as well as the GenTAC population using immunoassays and MRM, a mass spectrometry based breakthrough technology that allows for antibody-independent quantification. In a second step (Aim 2), we established an acute aortic dissection model in the mouse. This will enable us to expand de novo discovery to the acute setting and bridge the gap to biomarker discovery in the patient with acute dissection. We will validate our candidate markers using immunoassays and MRM and thereby gain further insight into prognosis of aortic dissection. As the TGFbeta family has been shown to play a key role in the development of MFS, we aim to develop a multiplex assay (Aim 3) with the ability to measure TGFbeta-1, -2 and - 3 simultaneously in a limited amount of sample. We recently gained the ability to measure TGFbeta in saliva. This might be an attractive option to "screen" patients for the activity of the aneurysm and provide guidance for the therapy in the individual patient. As many aspects of aortic disease, including diagnostic procedures and therapeutic measures, in patients with connective tissue disease are similar to those with a non-syndromatic background, insights from the current projects will contribute to the care for patients with aortic disease in general. Every year Johns Hopkins Institutions directly generate about $10 billion in economic activity in the State of Maryland, a 43% increase from the $7 billion generated in 2002 and the equivalent of one of every twenty-four dollars in the state's economy today. In 2008, Johns Hopkins Institutions provided 45,000 jobs and created 700 new jobs each year since 2002. Directly and indirectly Johns Hopkins Institutions support more than 100,000 jobs in Maryland, one of every 29 in the state. In Baltimore City alone Johns Hopkins directly and indirectly supports 60,000 jobs, or 16.7% of all City employment. PUBLIC HEALTH RELEVANCE: Acute dissections and ruptures of aortic aneurysms comprise for 1-2% of all deaths in industrialized countries. There is a pressing clinical need to find mechanisms that will (i) enable us to identify the patient at risk for a dissection among patients with known aortic aneurysms (ii) facilitate diagnosis of aortic dissection in the patient with acute chest pain and (iii) help us to individualize therapy. The current proposal will use proteomics techniques in an advanced animal model of aortic aneurysms and dissections to gain insight into these mechanisms and validate the findings in a large population of patients with aortic diseases.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1373/clinchem.2007.086611
发表时间: 2007-07
期刊: Clinical chemistry
影响因子: 9.3
作者: [Rebekah L. Gundry;J. V. Van Eyk]
通讯作者: Rebekah L. Gundry;J. V. Van Eyk
Milk fat globule protein epidermal growth factor-8: a pivotal relay element within the angiotensin II and monocyte chemoattractant protein-1 signaling cascade mediating vascular smooth muscle cells invasion.
牛奶脂肪球蛋白表皮生长因子-8:血管紧张素II和单核细胞趋化剂蛋白-1信号传导级联血管平滑肌细胞侵入的关键继电器元件。
DOI: 10.1161/circresaha.108.187088
发表时间: 2009-06-19
期刊: Circulation research
影响因子: 20.1
作者: [Fu Z, Wang M, Gucek M, Zhang J, Wu J, Jiang L, Monticone RE, Khazan B, Telljohann R, Mattison J, Sheng S, Cole RN, Spinetti G, Pintus G, Liu L, Kolodgie FD, Virmani R, Spurgeon H, Ingram DK, Everett AD, Lakatta EG, Van Eyk JE]
通讯作者: Van Eyk JE
DOI: 10.1016/j.jtcvs.2007.08.047
发表时间: 2008-02-01
期刊: JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
影响因子: 6
作者: [Matt, Peter, Habashi, Jennifer, Dietz, Harry C.]
通讯作者: Dietz, Harry C.
Mechanistic and Therapeutic Investigations of Scleroderma
  • 批准号:
    9304862
  • 项目类别:
  • 资助金额:
    $35.97万
  • 财政年份:
    2016
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
Systems Biology and Connective Tissue Disorders
  • 批准号:
    8063338
  • 项目类别:
  • 资助金额:
    $4.0万
  • 财政年份:
    2010
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
Novel Biomarkers in Aortic Aneurysms and Acute Aortic Dissection
  • 批准号:
    7815944
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2009
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
Molecular Biology of Marfan Syndrome
  • 批准号:
    7931831
  • 项目类别:
  • 资助金额:
    $28.31万
  • 财政年份:
    2009
  • 负责人:
    Harry C., III Dietz
  • 依托单位:
海外基金